Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China.
Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China; Collaborative Innovation Center of Systems Biomedicine of Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
EBioMedicine. 2019 Apr;42:481-493. doi: 10.1016/j.ebiom.2019.03.021. Epub 2019 Mar 14.
Although significant progress has been made in understanding the mechanisms of steatosis and insulin resistance, the physiological functions of the epigenetic regulators in these processes remain largely elusive.
Hepatocyte-specific Arid1a knockout mice were administrated with high-fat diet (HFD) for 12 weeks, then insulin sensitivity was assessed by glucose tolerance test (GTT) and insulin tolerance test (ITT). The metabolism-related indicators were determined by employing a variety of biological methods, including histology, real-time PCR, enzyme-linked immunosorbent assay (ELISA), Western blotting assay, Chromatin immunoprecipitation (ChIP), RNA-seq and assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq).
Hepatocyte-specific Arid1a deletion significantly increases susceptibility to develop hepatic steatosis, insulin resistance and inflammation in mice fed a HFD. In vitro, Arid1a deletion in isolated hepatocytes directly leads to free fatty acid-induced lipid accumulation and insulin resistance. Mechanically, Arid1a deficiency impairs fatty acid oxidation by downregulating PPARα and altering the epigenetic landscape of some metabolism genes.
These findings reveal that targeting Arid1a might be a promising therapeutic strategy for liver steatosis and insulin resistance. FUND: This work was supported by National Natural Science Foundation of China (81672772 and 81472621), China National Science and Technology Major Project for Prevention and Treatment of Infectious Diseases (No.2017ZX 10203207) and National Program on Key Research Project of China (grant no. 2016YFC0902701).
尽管在理解脂肪变性和胰岛素抵抗的机制方面已经取得了重大进展,但这些过程中表观遗传调节剂的生理功能在很大程度上仍未被揭示。
用高脂肪饮食(HFD)喂养 12 周特异性肝细胞敲除 Arid1a 的小鼠,然后通过葡萄糖耐量试验(GTT)和胰岛素耐量试验(ITT)评估胰岛素敏感性。采用组织学、实时 PCR、酶联免疫吸附试验(ELISA)、Western blot 检测、染色质免疫沉淀(ChIP)、RNA-seq 和高通量测序的转座酶可及染色质(ATAC-seq)检测等多种生物学方法测定代谢相关指标。
HFD 喂养的特异性肝细胞敲除 Arid1a 的小鼠肝脏脂肪变性、胰岛素抵抗和炎症易感性显著增加。在体外,分离的肝细胞中 Arid1a 的缺失直接导致游离脂肪酸诱导的脂质积累和胰岛素抵抗。机制上,Arid1a 缺乏通过下调 PPARα 并改变一些代谢基因的表观遗传景观来损害脂肪酸氧化。
这些发现表明,靶向 Arid1a 可能是治疗肝脏脂肪变性和胰岛素抵抗的一种有前途的策略。
本工作得到国家自然科学基金(81672772 和 81472621)、国家传染病防治重大专项(No.2017ZX 10203207)和国家重点研发计划(grant no. 2016YFC0902701)的资助。